Sustainability has been a recent focus of both pharmaceutical companies and stakeholders. In this episode of the Drug Solutions podcast, Patrick Lavery, editor for Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International®, gathers perspectives from five key opinion leaders across the industry about a variety of applications and equipment, and provides a look into how sustainable practices can be continued and improved upon in the years to come.

Adeno-associated virus (AAV) vectors have become widely used as delivery mechanisms in gene therapy, but there are some complex hurdles to be overcome. In this episode of the Drug Solutions podcast, Patrick Lavery, editor for Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International®, surveys two attendees from the recent ASGCT conference about their approaches, the results they have achieved so far, and what further research or investigation might be needed to bring these therapeutic tweaks to a wider cross-section of patients.

In this episode of Drug Solutions, the discussion revolves around current and anticipated new trends in equipment and technologies for optimizing the manufacture of new biotherapeutic modalities, such as cell and gene therapies. Automation technologies and continuous manufacturing emerges as significant drivers for the future biomanufacturing landscape. Innovative and progressive technologies will also play a role in establishing and maintain sustainabililty practices in the industry.

In this episode of the Drug Solutions podcast, Felicity Thomas, Associate Editorial Director, chats with a host of experts about the trends that have impacted the bio/pharma industry in 2024 and those they expect to be impactful in 2025.

In this episode of the Drug Solutions podcast, Felicity Thomas, Associate Editorial Director, chats with a host of experts about artificial intelligence (AI) and the potential impact AI and machine learning may have on the global bio/pharma industry in the near future.

Dosage forms, in particular oral solid dose, continue to evolve as new technologies enter the market, and as customer tastes and demands change. In this episode of the Drug Solutions podcast, Patrick Lavery, editor for Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International®, surveys attendees from the recent CPHI Milan gathering about how fast the market is expanding, how it's evolved in recent years and even decades, and what drugs are most conducive to OSD formulations.

The biopharmaceutical industry has long been working on methods to delivery biologic therapeutics in a manner that will enhance ease-of-use and patient compliance. Biologics today are largely administered parenterally, a method that can be painful and undesirable for patients. Furthermore, parenteral formulations of biologics require a strict temperature-controlled environment. Researchers have long been exploring means to formulate biologic-based molecules that can ensure their molecular stability and mitigate some of the stringent manufacturing requirements. In this episode of the Drug Solutions podcast, Feliza Mirasol, science editor of Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International® explores the issues challenging biologic formulation and the progress made so far in moving toward alternative routes of biologic drug delivery with Nigel Theobald, CEO of N4 Pharma, a specialist pharmaceutical company developing novel delivery systems for oncology, gene therapy and vaccines.

In this sponsored episode, Jörg Zimmermann from Vetter chats about fill/finish advances.

In this episode of the Drug Solutions podcast, Felicity Thomas, Associate Editorial Director, chats with Hanns-Christian Mahler, CEO and board member of ten23 health, about the growing demand for fill/finish services, technological advances and novel approaches helping to advance fill/finish, sustainable and green practices, the impact of smaller batch sizes, and regulatory guidance updates in the space. SPONSORS: Vetter

In this episode of the Drug Solutions podcast, Felicity Thomas, European/Senior Editor, chats with Alexander Natz, Secretary-General of EUCOPE, about the European Health Data Space (EHDS), which was formally adopted by the European Parliament in April 2024. The EHDS aims to improve access to and control of health data by individuals and also allow for secondary use of data in research, innovation, policy-making, and regulatory activities. SPONSORS: Solvias

In this episode of the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

In this episode of the Drug Solutions Podcast, industry experts give an overview of the biosimilars market and discuss factors affecting not only their manufacture, but their upstake in the market as well.

In this episode of the Drug Solutions Podcast, industry experts give an overview of the biosimilars market and discuss factors affecting not only their manufacture, but their upstake in the market as well.

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Tom Fletcher, director of Research and Development at FUJIFILM Irvine Scientific; and Bob Newman, PhD, chief scientific director at FUJIFILM Irvine Scientific, about formulation, specifically with how to prepare culture media for use, single use technologies, and automations to create closed systems in cell/gene therapies.

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.

The trend toward digital transformation in biopharmaceutical manufacturing continues as advanced technologies enter the scene and work their way through to manufacturing operations. With the availability of technologies to take automated biomanufacturing from preclinical to commercial-scale, the industry may start to see a wave of changeovers from manual processes to an automated, digital environment. This episode of the Drug Solutions Podcast will discuss the realities of switching over from manual to digital, and what to expect.

In this episode of the Drug Solutions Podcast, Shawn Liu, the president and CEO of Avirmax, relates his experience in entering the cell and gene therapy manufacturing space and how he began his own startup cell and gene therapy CDMO. SPONSOR: Lonza

Dr. Graziella Piras, senior director of Strategic Marketing at 908 Devices, discusses drug development, specifically about monitoring bioprocess parameters and other important technologies important to moving the process forward, with Pharmaceutical Technology editor Jill Murphy.

Chris Spivey, editorial director, hosts a wide ranging discussion on the COVID-19 pandemic response, future government communications, and healthcare funding for mRNA with experts Dr. Kate Broderick, Chief Innovation Officer, Maravai LifeSciences and Dr. Tom Madden, President & CEO at Acuitas Therapeutics.

In this episode of the Drug Solutions podcast, Felicity Thomas, European/Senior Editor, talks to David Tisi, technical director at Senopsys LLC, and Reenal Gandhi, global business development director for the Prescription Division of Aptar Pharma. In the first segment of the episode, David chats about some of the key challenges impacting oral dosage forms and the approaches and solutions available that are helping developers overcome these hurdles. After, Reenal details the intricacies of intranasal drug dosage forms, such as the convenience and the growth of this route of administration, challenges of development, and the possibilities of repositioning drug products. SPONSOR: Lonza